References
- Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(2):18-23
- Myers WA, Gottlieb AB, Mease P, et al. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006;24(5):438-47
- Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol 2007;25(6):510-18
- Kwon HH, Na SJ, Jo SJ, et al. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol 2011;39(3):260-4
- Syed Z, Khachemoune A. Inverse psoriasis: case presentation and review. Am J Clin Dermatol 2011;12(2):143-6
- Choon S, Lai N, Mohammad N, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2013; Epub ahead of print
- Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005;5(9):699-711
- Gudjonsson JE, Karason A, Antonsdottir A, et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol 2003;148(2):233-5
- Becher B, Pantelyushin S. Hiding under the skin: interleukin-17–producing γδ T cells go under the skin? Nat Med 2012;18:1748-50
- Tracey D, Klareskog L, Sasso E, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117(2):244-79
- Capon F. IL36RN mutations in generalized pustular psoriasis: just the tip of the Iceberg? J Investig Dermatol 2013;133:2503-4
- Medzhitov R, Janeway CA Jr. Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997;9(1):4-9
- Connolly D, O'Neill L. New developments in toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012;12(4):510-18
- Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-α) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003;21(5):392-7
- Matsushima K. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine 1989;1(1):2-13
- Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29(1):3-9
- Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (Cytotoxic T Lymphocyte) and TH1 effector populations:1 a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Investig Dermatol 1999;113(5):752-9
- Griffiths CE, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 2001;26(4):338-42
- Arnetz BB, Fjellner B, Eneroth P, et al. Stress and psoriasis: psychoendocrine and metabolic reactions in psoriatic patients during standardized stressor exposure. Psychosom Med 1985;47(6):528-41
- Crow JM. Therapeutics: silencing psoriasis. Nature 2012;492(7429):S58-9